Search PubMedSearch

PubMed · 42539208

HPRC2: A human pangenome reference with near-complete coverage of common genetic variation.

Julian K Lucas·Prajna Hebbar·Wen-Wei Liao·Juan F Macias-Velasco·Adam M Novak·Mobin Asri·Jennifer R Balacco·Andrew P Blair·Davide Bolognini·Jana Ebler·Joshua M V Gardner·Margarita Geleta·Cristian Groza·Andrea Guarracino·Peter Heringer·Glenn Hickey·Sergey Koren·Shuangjia Lu·Maximillian G Marin·Christopher Markovic·Mira Mastoras·Capucine Mayoud·Brandy McNulty·Julian M Menendez·Anna Minkina·Saswat K Mohanty·Jean Monlong·Katherine M Munson·Keisuke K Oshima·David Porubsky·T Rhyker Ranallo-Benavidez·Alessandro Raveane·William E Seligmann·Ruhollah Shemirani·Yoshihiko Suzuki·Jack A S Tierney·Ivo Violich·DongAhn Yoo·Xiaoyu Zhuo·Derek Albracht·Ivan A Alexandrov·Jamie Allen·Alawi A Alsheikh-Ali·Casey Andrews·Dmitry Antipov·Lucinda Antonacci-Fulton·Alexander Arguello·Marcelo Ayllon·Edward A Belter·Halle D Bender·Katherine E Bonini·Silvia Buonaiuto·Shuo Cao·Ann M Mc Cartney·Pi-Chuan Chang·Xian Chang·Jitender Cheema·Claudio Ciofi·Hiram Clawson·Sarah Cody·Vincenza Colonna·Holland C Conwell·Mark Diekhans·Maria Angela Diroma·Zheng Dong·Danilo Dubocanin·Jordan M Eizenga·Parsa Eskandar·Eddie Ferro·Sarah M Ford·Willard W Ford·Adam Frankish·Mallory A Freeberg·Qichen Fu·Shenghan Gao·Yan Gao·Gage H Garcia·Obed A Garcia·John E Garza·Mohammadmersad Ghorbani·Tina A Graves-Lindsay·Bida Gu·Leanne Haggerty·Nancy F Hansen·Yue Hao·Todd L Hillaker·S Nakib Hossain·Neng Huang·Sarah E Hunt·Toby Hunt·Nafiseh Jafarzadeh·Nivesh Jain·Maryam Jehangir·Juan Jiang·Juhyun Kim·Bonhwang Koo·Milinn Kremitzki·Daofeng Li·Ronghan Li·Jiadong Lin

Abstract

A pangenome reference overcomes the inherent limitation of any individual reference genome by integrating the variation present in a population. We present the Human Pangenome Reference Consortium's (HPRC) Release 2 (HPRC2), an openly available, second phase pangenome that is an approximately fivefold expansion in genome number over HPRC Release 1 (HPRC1) and measurable improvement in genome completeness, contiguity, and accuracy. Selecting samples with a principled algorithm prioritising common variant coverage, HPRC2 contributes 460 haplotypes that together capture over 99% of common variation observed in the All of Us Research Program v8 cohort. Combining high-coverage long and ultra-long reads with modern assemblers and polishers, we produce thousands of telomere-to-telomere (T2T) chromosomes, and relative to HPRC1 halve the number of structurally unreliable regions as well as individual base errors per haplotype. We complement the assemblies with whole genome multiple alignments and gene annotations, and derive formal pangenome coordinate systems for addressing off-reference variation, demonstrating that individual human genomes contain more than one hundred thousand variants not succinctly described with respect to existing reference genomes. We also present the first matched long-read backed pantranscriptome and panepigenome at this scale, provide continuous local-ancestry estimates spanning every genome, and outline a host of new tools and applications that leverage the pangenome resource for improved genomics analysis.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Julian K Lucas, Prajna Hebbar, Wen-Wei Liao, Juan F Macias-Velasco, Adam M Novak, Mobin Asri, Jennifer R Balacco, Andrew P Blair, Davide Bolognini, Jana Ebler, Joshua M V Gardner, Margarita Geleta, Cristian Groza, Andrea Guarracino, Peter Heringer, Glenn Hickey, Sergey Koren, Shuangjia Lu, Maximillian G Marin, Christopher Markovic, Mira Mastoras, Capucine Mayoud, Brandy McNulty, Julian M Menendez, Anna Minkina, Saswat K Mohanty, Jean Monlong, Katherine M Munson, Keisuke K Oshima, David Porubsky, T Rhyker Ranallo-Benavidez, Alessandro Raveane, William E Seligmann, Ruhollah Shemirani, Yoshihiko Suzuki, Jack A S Tierney, Ivo Violich, DongAhn Yoo, Xiaoyu Zhuo, Derek Albracht, Ivan A Alexandrov, Jamie Allen, Alawi A Alsheikh-Ali, Casey Andrews, Dmitry Antipov, Lucinda Antonacci-Fulton, Alexander Arguello, Marcelo Ayllon, Edward A Belter, Halle D Bender, Katherine E Bonini, Silvia Buonaiuto, Shuo Cao, Ann M Mc Cartney, Pi-Chuan Chang, Xian Chang, Jitender Cheema, Claudio Ciofi, Hiram Clawson, Sarah Cody, Vincenza Colonna, Holland C Conwell, Mark Diekhans, Maria Angela Diroma, Zheng Dong, Danilo Dubocanin, Jordan M Eizenga, Parsa Eskandar, Eddie Ferro, Sarah M Ford, Willard W Ford, Adam Frankish, Mallory A Freeberg, Qichen Fu, Shenghan Gao, Yan Gao, Gage H Garcia, Obed A Garcia, John E Garza, Mohammadmersad Ghorbani, Tina A Graves-Lindsay, Bida Gu, Leanne Haggerty, Nancy F Hansen, Yue Hao, Todd L Hillaker, S Nakib Hossain, Neng Huang, Sarah E Hunt, Toby Hunt, Nafiseh Jafarzadeh, Nivesh Jain, Maryam Jehangir, Juan Jiang, Juhyun Kim, Bonhwang Koo, Milinn Kremitzki, Daofeng Li, Ronghan Li, Jiadong Lin. 2026-07-22. HPRC2: A human pangenome reference with near-complete coverage of common genetic variation.. https://doi.org/10.64898/2026.07.21.739710

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article